Sopharma AD Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Ognian Donev

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	23.9yrs
Eigentum des Geschäftsführers	8.8%
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	9.7yrs

Jüngste Management Updates

Recent updates

Geschäftsführer

Ognian Donev (67 yo)

23.9yrs

Amtszeit

лв723,162

Vergütung

Mr. Ognian Ivanov Donev, D.Sc. (Econ.), Ph D., serves as the Executive Chairman at Sopharma AD and Sopharma Trading AD and also served as Chief Executive Officer since September 2021 until November 2021. M...

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Ognian Donev	Chairman	23.9yrs	лв723.16k	8.76% BGN 86.0m
Vessela Stoeva	Deputy Chairman	no data	лв173.75k	0.000090% BGN 883.0
Ivan Badinski	Director	6.1yrs	лв252.59k	0.0012% BGN 12.0k
Alexandar Tchaoushev	Independent Director	13.3yrs	лв120.00k	0.27% BGN 2.6m
Bissera Lazarova	Director	3.3yrs	keine Daten	0.021% BGN 202.5k

9.7yrs

Durchschnittliche Betriebszugehörigkeit

61yo

Durchschnittliches Alter

Erfahrener Vorstand: SFADie Vorstandsmitglieder gelten als erfahren (9.6 Jahre durchschnittliche Amtszeit).

Sopharma AD Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Independent Director recently bought лв331k worth of stock

Chairman recently bought лв124k worth of stock

Chairman recently sold лв527k worth of stock

Sopharma AD, Annual General Meeting, Jun 30, 2024

Chairman recently bought лв338k worth of stock

Chairman recently bought лв72k worth of stock

Recent updates

Sopharma AD's (BUL:SFA) Problems Go Beyond Weak Profit

Second quarter 2024 earnings released: EPS: лв0.081 (vs лв0.26 in 2Q 2023)

Independent Director recently bought лв331k worth of stock

Chairman recently bought лв124k worth of stock

First quarter 2024 earnings released: EPS: лв0.23 (vs лв0.27 in 1Q 2023)

Here's Why Sopharma AD (BUL:SFA) Can Manage Its Debt Responsibly

Now 23% overvalued after recent price rise

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Chairman recently sold лв527k worth of stock

Sopharma AD, Annual General Meeting, Jun 30, 2024

Chairman recently bought лв338k worth of stock

New major risk - Financial position

Third quarter 2023 earnings released: EPS: лв0.12 (vs лв0.20 in 3Q 2022)

Upcoming dividend of лв0.90 per share at 8.4% yield

Sopharma AD Approves Distribution for the First Half of 2023, Payable on January 22, 2024

New minor risk - Share price stability

Sopharma AD to Report Q3, 2023 Results on Nov 29, 2023

New minor risk - Shareholder dilution

Chairman recently bought лв72k worth of stock

Investor sentiment improves as stock rises 17%

Sopharma AD to Report Q3, 2023 Results on Oct 30, 2023

Chairman recently bought лв81k worth of stock

Chairman recently sold лв1.1m worth of stock

Sopharma AD (BUL:SFA) acquired a 2.38% stake in Sopharma Buildings REIT-Sofia.

Second quarter 2023 earnings released: EPS: лв0.25 (vs лв0.19 in 2Q 2022)

New minor risk - Shareholder dilution

Sopharma AD (BUL:SFA) signed an agreement to acquire Pharmanova d.o.o.

Chairman recently sold лв297k worth of stock

New minor risk - Dividend sustainability

Upcoming dividend of лв0.60 per share

Sopharma AD Declares Dividend for 2022, Payable on 31 July 2023

First quarter 2023 earnings released: EPS: лв0.27 (vs лв0.17 in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations

Sopharma AD, Annual General Meeting, Jun 30, 2023

Sopharma AD to Report Fiscal Year 2023 Results on Mar 29, 2024

Consensus EPS estimates increase by 83%

Price target increased to лв4.83

Third quarter 2022 earnings released: EPS: лв0.20 (vs лв0.14 in 3Q 2021)

Less than half of directors are independent

Second quarter 2022 earnings released: EPS: лв0.19 (vs лв0.12 in 2Q 2021)

Sopharma AD (BUL:SFA) made the offer to acquire remaining 66.66% stake in Sopharma Properties REIT (BUL:SFI) for approximately BGN 120 million.

First quarter 2022 earnings released: EPS: лв0.17 (vs лв0.14 in 1Q 2021)

Sopharma AD, Annual General Meeting, Jun 03, 2022

Less than half of directors are independent

Sopharma AD to Report Fiscal Year 2021 Final Results on Apr 29, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Sopharma AD to Report Fiscal Year 2021 Results on Mar 31, 2022

An unknown buyer has agreed to acquire SIA BRIZ from Sopharma AD (BUL:SFA).

Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Second quarter 2021 earnings released

Chairman recently bought лв79k worth of stock

Price target decreased to лв3.48

Price target decreased to лв3.48

First quarter 2021 earnings released

Sopharma AD (BUL:SFA) Has A Somewhat Strained Balance Sheet

Full year 2020 earnings released: EPS лв0.20 (vs лв0.69 in FY 2019)

New 90-day high: лв3.50

Here's Why We Think Sopharma AD (BUL:3JR) Is Well Worth Watching

How Many Sopharma AD (BUL:3JR) Shares Do Institutions Own?

Should You Rely On Sopharma AD's (BUL:3JR) Earnings Growth?

New 90-day high: лв3.26

Sopharma AD (BUL:3JR) acquired an unknown minority stake in SIA BRIZ.

Sopharma AD (BUL:3JR) Has A Somewhat Strained Balance Sheet

An unknown buyer acquired majority stake of Aromania OOD from Sopharma AD (BUL:3JR).

Sopharma AD (BUL:3JR) Share Prices Have Dropped 25% In The Last Three Years

New 90-day high: лв3.18

Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?

Are Investors Undervaluing Sopharma AD (BUL:3JR) By 29%?